A study of 180 bladder tumors finds that survival drops only when the high-grade component exceeds 27.5 percent, far above ...

Add Yahoo as a preferred source to see more of our stories on Google. Patients with advanced bladder cancer have significantly less risk of the disease progressing or returning when treated with an ...

The vast majority of Australia's bladder cancer cases are in men, but experts are concerned about the number of women ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...

ImmunityBio (IBRX) stock fell 7.25% to $9.27 despite ANKTIVA trial results showing a 71% response rate and lasting benefits ...

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

Circulating tumour DNA (ctDNA) monitoring identified patients with muscle-invasive bladder cancer who showed significantly longer disease-free survival and overall survival when treated with adjuvant ...

Add Yahoo as a preferred source to see more of our stories on Google. A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced ...

Whole pelvis radiation improves cancer-specific and overall survival in muscle-invasive bladder cancer compared to bladder-only radiation. Median cancer-specific survival was 84 months for whole ...

Sasanlimab combined with BCG significantly improves event-free survival in BCG-naïve, high-risk NMIBC patients compared to BCG alone. The CREST trial's phase 3 results suggest sasanlimab may redefine ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...